Integrated Molecular and Clinical Analysis of AKT Activation in Metastatic Melanoma

Purpose: Activation of the phosphoinositide 3-kinase (PI3K)-AKT pathway has been implicated in melanoma based primarily on the prevalence of mutations in PTEN and NRAS. To improve our understanding of the regulation and clinical significance of the PI3K-AKT pathway in melanoma, we quantitatively measured the levels of phosphorylated AKT, its substrate GSK3α/β, and its negative regulator PTEN in clinical metastases. Results were compared with mutational status, clinical outcomes, and sites of metastasis. Experimental Design: DNA and protein were isolated from dissected frozen melanoma metastases (n = 96). Activating mutations of BRAF, NRAS, AKT, PIK3CA, and KIT were detected by mass spectroscopy genotyping. Phosphorylated AKT (Ser473 and Thr308), P-GSK3α/β, and PTEN protein expression were measured by reverse-phase protein array. A panel of human melanoma cells lines (n = 58) was analyzed for comparison. Results: BRAF-mutant tumors had higher levels of P-AKT-Ser473 (P = 0.01), P-AKT-Thr308 (P = 0.002), and P-GSK3α/β (P = 0.08) than NRAS-mutant tumors. Analysis of individual tumors showed that almost all tumors with elevated P-AKT had low PTEN levels; NRAS-mutant tumors had normal PTEN and lower P-AKT. Similar results were observed in melanoma cell lines. Stage III melanoma patients did not differ in overall survival based on activation status of the PI3K-AKT pathway. Brain metastases had significantly higher P-AKT and lower PTEN than lung or liver metastases. Conclusions: Quantitative interrogation of the PI3K-AKT pathway in melanoma reveals unexpected significant differences in AKT activation by NRAS mutation and PTEN loss, and hyperactivation of AKT in brain metastases. These findings have implications for the rational development of targeted therapy for this disease. (Clin Cancer Res 2009;15(24):7538–46)

[1]  Alessandra Marini,et al.  Epigenetic silencing of the PTEN gene in melanoma. , 2006, Cancer research.

[2]  Yiling Lu,et al.  Exploiting the PI3K/AKT Pathway for Cancer Drug Discovery , 2005, Nature Reviews Drug Discovery.

[3]  F. Haluska,et al.  Genetic interaction between NRAS and BRAF mutations and PTEN/MMAC1 inactivation in melanoma. , 2004, The Journal of investigative dermatology.

[4]  Yiling Lu,et al.  Pharmacodynamic Markers of Perifosine Efficacy , 2007, Clinical Cancer Research.

[5]  P. Dhawan,et al.  Constitutive activation of Akt/protein kinase B in melanoma leads to up-regulation of nuclear factor-kappaB and tumor progression. , 2002, Cancer research.

[6]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.

[7]  A. Jemal,et al.  Cancer Statistics, 2009 , 2009, CA: a cancer journal for clinicians.

[8]  Michael J. Fry,et al.  Phosphatidylinositol-3-OH kinase direct target of Ras , 1994, Nature.

[9]  J. Hansson,et al.  Mutations of PIK3CA are rare in cutaneous melanoma , 2006, Melanoma research.

[10]  Kevin B. Kim,et al.  Analysis of protein tyrosine kinases expression in the melanoma metastases of patients treated with Imatinib Mesylate (STI571, GleevecTM) , 2006, Journal of cutaneous pathology.

[11]  G. Mills,et al.  A novel AKT3 mutation in melanoma tumours and cell lines , 2008, British Journal of Cancer.

[12]  Yiling Lu,et al.  AKT-independent signaling downstream of oncogenic PIK3CA mutations in human cancer. , 2009, Cancer cell.

[13]  A. Friedman,et al.  Demographics, prognosis, and therapy in 702 patients with brain metastases from malignant melanoma. , 1998, Journal of neurosurgery.

[14]  I. Fidler,et al.  Transforming growth factor-beta2 is a molecular determinant for site-specific melanoma metastasis in the brain. , 2009, Cancer research.

[15]  J. Hansson,et al.  Lack of cytoplasmic ERK activation is an independent adverse prognostic factor in primary cutaneous melanoma. , 2008, The Journal of investigative dermatology.

[16]  A. Nicholson,et al.  Mutations of the BRAF gene in human cancer , 2002, Nature.

[17]  Emanuel F Petricoin,et al.  Protein microarrays: meeting analytical challenges for clinical applications. , 2003, Cancer cell.

[18]  K. Flaherty,et al.  Phase I study of PLX4032: Proof of concept for V600E BRAF mutation as a therapeutic target in human cancer. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  V. A. Flørenes,et al.  Expression of activated Akt and PTEN in malignant melanomas: relationship with clinical outcome. , 2005, American journal of clinical pathology.

[20]  K. Shannon,et al.  Determinants of outcome in melanoma patients with cerebral metastases. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  J. Cheng,et al.  Deregulated Akt3 Activity Promotes Development of Malignant Melanoma , 2004, Cancer Research.

[22]  M. Loda,et al.  The oncogenic properties of mutant p110α and p110β phosphatidylinositol 3-kinases in human mammary epithelial cells , 2005 .

[23]  R. Jope,et al.  The multifaceted roles of glycogen synthase kinase 3β in cellular signaling , 2001, Progress in Neurobiology.

[24]  M. Ringnér,et al.  Poor prognosis in carcinoma is associated with a gene expression signature of aberrant PTEN tumor suppressor pathway activity , 2007, Proceedings of the National Academy of Sciences.

[25]  F. Haluska,et al.  Identification of PTEN/MMAC1 alterations in uncultured melanomas and melanoma cell lines , 1998, Oncogene.

[26]  K. Aldape,et al.  Activation of stat3 in human melanoma promotes brain metastasis. , 2006, Cancer research.

[27]  M. Ratain,et al.  Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis , 2006, British Journal of Cancer.

[28]  J. Shay,et al.  BRAFE600-associated senescence-like cell cycle arrest of human naevi , 2005, Nature.

[29]  Zhi Hu,et al.  An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer. , 2008, Cancer research.

[30]  N. Hay,et al.  Akt determines replicative senescence and oxidative or oncogenic premature senescence and sensitizes cells to oxidative apoptosis. , 2008, Cancer cell.

[31]  M. Herlyn,et al.  Reciprocal regulation of MelCAM and AKT in human melanoma , 2003, Oncogene.

[32]  D. Pinkel,et al.  PI3-kinase subunits are infrequent somatic targets in melanoma. , 2006, The Journal of investigative dermatology.

[33]  G. Robertson,et al.  Loss of PTEN promotes tumor development in malignant melanoma. , 2003, Cancer research.

[34]  S. Gabriel,et al.  High-throughput oncogene mutation profiling in human cancer , 2007, Nature Genetics.

[35]  C. Shea,et al.  Recurrent melanocytic nevus: a histologic and immunohistochemical evaluation , 2001, Journal of cutaneous pathology.

[36]  P. Khavari,et al.  Use of human tissue to assess the oncogenic activity of melanoma-associated mutations , 2005, Nature Genetics.

[37]  M. Flaig,et al.  Mutations of the BRAF gene in benign and malignant melanocytic lesions. , 2003, The Journal of investigative dermatology.

[38]  M. Martinka,et al.  Prognostic significance of activated Akt expression in melanoma: a clinicopathologic study of 292 cases. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  Michael B Atkins,et al.  Management of cutaneous melanoma. , 2004, The New England journal of medicine.

[40]  C. Warneke,et al.  Examination of mutations in BRAF, NRAS, and PTEN in primary cutaneous melanoma. , 2006, The Journal of investigative dermatology.

[41]  Frank McCormick,et al.  High frequency of coexistent mutations of PIK3CA and PTEN genes in endometrial carcinoma. , 2005, Cancer research.

[42]  H. Tsao,et al.  Ultraviolet radiation and melanoma: a systematic review and analysis of reported sequence variants , 2007, Human mutation.

[43]  C. Eng,et al.  Epigenetic PTEN silencing in malignant melanomas without PTEN mutation. , 2000, The American journal of pathology.

[44]  F. Haluska,et al.  Relative reciprocity of NRAS and PTEN/MMAC1 alterations in cutaneous melanoma cell lines. , 2000, Cancer research.

[45]  L. Zon,et al.  BRAF Mutations Are Sufficient to Promote Nevi Formation and Cooperate with p53 in the Genesis of Melanoma , 2005, Current Biology.

[46]  Huan Yang,et al.  MicroRNA expression profiling in human ovarian cancer: miR-214 induces cell survival and cisplatin resistance by targeting PTEN. , 2008, Cancer research.

[47]  G. Mills,et al.  Adenoviral transgene expression of MMAC/PTEN in human glioma cells inhibits Akt activation and induces anoikis. , 1998, Cancer research.

[48]  G. Robertson,et al.  Targeting V600EB-Raf and Akt3 using nanoliposomal-small interfering RNA inhibits cutaneous melanocytic lesion development. , 2008, Cancer research.

[49]  L. Tanoue.  Cancer Statistics, 2009 , 2010 .

[50]  G. Mills,et al.  Reverse phase protein array: validation of a novel proteomic technology and utility for analysis of primary leukemia specimens and hematopoietic stem cells , 2006, Molecular Cancer Therapeutics.

[51]  P. Meltzer,et al.  High frequency of BRAF mutations in nevi , 2003, Nature Genetics.

[52]  K. Shokat,et al.  PIK3CA cooperates with other phosphatidylinositol 3'-kinase pathway mutations to effect oncogenic transformation. , 2008, Cancer research.